Substantial underdiagnosis of lymphogranuloma venereum in men who have sex with men in Europe: preliminary findings from a multicentre surveillance pilot.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
03 2020
Historique:
received: 14 01 2019
revised: 30 04 2019
accepted: 19 05 2019
pubmed: 27 6 2019
medline: 1 7 2020
entrez: 26 6 2019
Statut: ppublish

Résumé

Understanding the public health impact of lymphogranuloma venereum (LGV) in Europe is hampered by inadequate diagnostics and surveillance systems in many European countries. We developed and piloted LGV surveillance in three European countries without existing systems and performed a preliminary investigation of LGV epidemiology, where little evidence currently exists. We recruited STI or dermatovenereology clinics and associated laboratories serving men who have sex with men (MSM) in Austria, Croatia and Slovenia, using the UK for comparison. We undertook centralised LGV testing of In total, 500 specimens from CT-positive MSM were tested, and LGV positivity was 25.6% (128/500; 95% CI 22.0% to 29.6%) overall, and 47.6% (79/166; 40.1% to 55.2%) in Austria, 20.0% (3/15; 7.1% to 45.2%) in Croatia, 16.7% (1/6; 3.0% to 56.4%) in Slovenia and 14.4% (45/313; 10.9% to 18.7 %) in the UK. Proformas were completed for cases in Croatia, Slovenia and in the UK; proformas could not be completed for Austrian cases, but limited data were available from line listings. Where recorded, 83.9% (78/93) of LGV-CT cases were HIV-positive compared with 65.4% (149/228) of non-LGV-CT cases; MSM with LGV-CT were more likely to have proctitis (Austria, 91.8% vs 40.5%, p<0.001; Croatia, 100% vs 25%, p=0.04; UK, 52.4% vs 11.7%, p<0.001) than those with non-LGV-CT. Six different LGV is substantially underdiagnosed in MSM across Europe. Unified efforts are needed to overcome barriers to testing, establish effective surveillance, and optimise diagnosis, treatment and prevention.

Identifiants

pubmed: 31235527
pii: sextrans-2019-053972
doi: 10.1136/sextrans-2019-053972
pmc: PMC7035679
doi:

Substances chimiques

Bacterial Outer Membrane Proteins 0
OMPA outer membrane proteins 149024-69-1

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

137-142

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Euro Surveill. 2016;21(11):30165
pubmed: 27020297
Emerg Infect Dis. 2005 Jul;11(7):1090-2
pubmed: 16022786
Emerg Infect Dis. 2013 Mar;19(3):488-92
pubmed: 23621949
Emerg Infect Dis. 2016 Jan;22(1):112-116
pubmed: 26691688
Emerg Infect Dis. 2018 Apr;24(4):806-808
pubmed: 29553338
Sex Transm Dis. 2007 Jul;34(7):451-5
pubmed: 17075436
BMC Infect Dis. 2017 Sep 11;17(1):617
pubmed: 28893203
Lancet. 2013 Apr 20;381(9875):1358-1359
pubmed: 23601946
Euro Surveill. 2017 Feb 2;22(5):
pubmed: 28183394
Clin Microbiol Infect. 2014 Mar;20(3):219-25
pubmed: 23730727
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S865-73
pubmed: 26602624
Euro Surveill. 2016;21(5):2-5
pubmed: 26889644
Can Fam Physician. 2016 Jul;62(7):554-8
pubmed: 27412206
Int J STD AIDS. 2016 Mar;27(4):251-67
pubmed: 26538553
J Clin Microbiol. 1993 May;31(5):1060-5
pubmed: 8099080
Euro Surveill. 2014 Dec 04;19(48):20981
pubmed: 25496573
Emerg Infect Dis. 2016 Nov;22(11):1945-1947
pubmed: 27767927
BMC Public Health. 2016 Jul 07;16:525
pubmed: 27386950
Sex Transm Infect. 2014 Jun;90(4):275-8
pubmed: 24431182
Emerg Infect Dis. 2005 Aug;11(8):1311-2
pubmed: 16110579
J Eur Acad Dermatol Venereol. 2015 Jan;29(1):1-6
pubmed: 24661352
Nat Genet. 2012 Mar 11;44(4):413-9, S1
pubmed: 22406642
Euro Surveill. 2015;20(48):30076
pubmed: 26675210
Sex Transm Infect. 2013 Nov;89(7):542-7
pubmed: 23851189

Auteurs

Michelle Jayne Cole (MJ)

National Infection Service, Public Health England, London, UK Michelle.Cole@phe.gov.uk.

Nigel Field (N)

National Infection Service, Public Health England, London, UK.
Research Department of Infection and Population Health, University College London, London, UK.

Rachel Pitt (R)

National Infection Service, Public Health England, London, UK.

Andrew J Amato-Gauci (AJ)

Office of the Chief Scientist, European Centre for Disease Prevention and Control, Stockholm, Sweden.

Josip Begovac (J)

University Hospital for Infectious Diseases 'Dr Fran Mihaljevic', Zagreb, Croatia.

Patrick D French (PD)

Mortimer Market, UCLH, Camden Primary Care Trust, London, UK.

Darja Keše (D)

Institute of Microbiology and Immunology, Ljubljana, Slovenia.

Irena Klavs (I)

Institut za varovanje zdravja Republike Slovenije, Ljubljana, Slovenia.

Snjezana Zidovec Lepej (S)

University Hospital for Infectious Diseases 'Dr Fran Mihaljevic', Zagreb, Croatia.

Katharina Pöcher (K)

Outpatients' Centre for Diagnosis of Infectious Venero-Dermatological Diseases, Vienna, Austria.

Angelika Stary (A)

Outpatients' Centre for Diagnosis of Infectious Venero-Dermatological Diseases, Vienna, Austria.

Horst Schalk (H)

Practice for General Medicine, Vienna, Austria.

Gianfranco Spiteri (G)

Surveillance and Response Support Unit, European Centre for Disease Prevention and Control, Stockholm, Sweden.

Gwenda Hughes (G)

National Infection Service, Public Health England, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH